REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $4.37 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-09-30 was $4.43, a 12.62% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-09-30 was $5.07, a 18.36% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-09-30 was $6.21, a 64.12% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2022-09-30 was $17.31, a 17.85% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2026 was $4.37, a 2.46% decline from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $4.48, a 16.88% decline from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $5.39, a 17.96% decline from fiscal 2023.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $6.57, a 64.73% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.37 10-K · filed 2026-09-24 | ||||
| 2026-03-31 | $4.41 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $4.34 10-Q · filed 2026-02-12 | ||||
| 2025-09-30 | $4.43 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $4.48 10-K · filed 2026-09-24 | ||||
| 2025-03-31 | $4.61 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $4.87 10-Q · filed 2025-02-12 | ||||
| 2024-09-30 | $5.07 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $5.39 10-K · filed 2025-09-17 | ||||
| 2024-03-31 | $5.59 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $5.91 10-Q · filed 2024-02-13 | ||||
| 2023-09-30 | $6.21 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $6.57 10-K · filed 2024-09-19 | ||||
| 2023-03-31 | $11.65 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $16.31 10-Q · filed 2023-02-10 | ||||
| 2022-09-30 | $17.31 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $18.63 10-K · filed 2023-09-14 | ||||
| 2022-03-31 | $19.23 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $20.13 10-Q · filed 2022-02-09 | ||||
| 2021-09-30 | $21.07 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $23.07 10-K · filed 2022-09-15 | ||||
| 2021-03-31 | $38.02 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $48.56 10-Q · filed 2021-02-10 | ||||
| 2020-09-30 | $50.36 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $53.14 10-K · filed 2021-09-15 | ||||
| 2020-03-31 | $1.12 10-Q · filed 2020-05-14 | ||||
| 2019-12-31 | $1.20 10-Q · filed 2020-02-12 | ||||
| 2019-09-30 | $1.27 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $92.50 10-K · filed 2020-10-13 | $1.85 10-K · filed 2019-09-10 | |||
| 2018-06-30 | $1.92 10-K · filed 2019-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |